NCT02131597View on ClinicalTrials.gov

Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 10, 2014

Primary Completion Date

July 25, 2024

Study Completion Date

July 25, 2024

Conditions
High Risk Myelodysplastic Syndrome
Interventions
DRUG

Guadecitabine

Given SC

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02131597 - Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter